Dr. Lal Path Labs Ltd. CC-Nov25.pdf · 2025-10-31
Hi. Thank you for the opportunity. So, it was mentioned in the presentation as new therapies for diabetes are increasing, the role of diagnostics will intensify. With weight loss drugs going off patent next year, do you intend to plan test bundles which will cater to GLP-1? And how do you see this opportunity?
Okay. And secondly, in the industry, Q3 is generally a softer quarter. But with monsoon being extended this time, do you see more volumes the next quarter?